Kangmei Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1,363	1,240	977.84	1,057	1,507	2,419
Trading Asset Securities	0.08	0.09	0.08	0.08	0.12	0.52
Cash & Short-Term Investments	1,363	1,240	977.92	1,057	1,508	2,419
Cash Growth	15.46%	26.82%	-7.45%	-29.90%	-37.68%	337.98%
Accounts Receivable	2,199	2,424	2,391	2,095	2,046	1,460
Other Receivables	460.39	593.1	823.86	874.44	888.79	1,052
Receivables	2,659	3,018	3,215	2,969	2,935	2,512
Inventory	2,391	2,237	2,510	2,644	2,751	3,195
Prepaid Expenses	-	-	-	-	0	-
Other Current Assets	205.73	157.22	197.17	139.97	190.85	158.8
Total Current Assets	6,619	6,651	6,900	6,810	7,384	8,285
Property, Plant & Equipment	3,327	3,451	3,500	3,875	4,180	4,642
Long-Term Investments	1.05	1.04	1.11	1.15	1.39	1
Goodwill	36.91	36.91	106.35	106.35	106.35	106.35
Other Intangible Assets	401.39	413.93	409.47	491.02	529.79	579.73
Long-Term Deferred Tax Assets	59.78	64.17	74.36	101.48	96.97	60.69
Long-Term Deferred Charges	44.01	49.99	55.05	66.47	86.71	110.22
Other Long-Term Assets	2,424	2,551	2,752	2,829	2,783	2,269
Total Assets	12,913	13,220	13,798	14,280	15,169	16,054

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	2,233	2,355	2,546	2,256	2,563	2,015
Accrued Expenses	56	495.68	520.42	716.97	1,328	1,134
Short-Term Debt	51.73	90.93	15.83	26.14	25.62	15.17
Current Portion of Long-Term Debt	27.78	-	-	-	-	-
Current Portion of Leases	-	23.54	28.35	40.71	39.12	36.89
Current Income Taxes Payable	417.48	37.09	27.7	24.74	26.2	140.5
Current Unearned Revenue	112.54	91.7	118.82	159.89	158.12	193.85
Other Current Liabilities	1,991	2,172	2,637	2,875	1,301	1,411
Total Current Liabilities	4,890	5,266	5,894	6,100	5,442	4,947
Long-Term Leases	72.77	69.89	94.95	188.16	199.13	153.22
Long-Term Unearned Revenue	502.77	523.01	555.78	618.68	653.98	692.97
Long-Term Deferred Tax Liabilities	21.3	19.3	26.85	51.68	55.53	-
Other Long-Term Liabilities	4.85	16.25	17.79	241.31	1,835	293.02
Total Liabilities	5,492	5,894	6,589	7,200	8,185	6,086

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	13,829	13,829	13,864	13,864	13,864	13,864
Additional Paid-In Capital	18,474	18,474	18,783	18,783	18,783	18,783
Retained Earnings	-24,263	-24,356	-24,367	-24,375	-24,478	-21,790
Treasury Stock	-659.92	-659.92	-1,107	-1,225	-1,222	-932.82
Comprehensive Income & Other	2.83	3.23	1.18	1.18	1.43	3.1
Total Common Equity	7,383	7,290	7,174	7,048	6,948	9,927
Minority Interest	37.84	35.4	34.55	32.89	35.43	41.92
Shareholders' Equity	7,421	7,325	7,209	7,080	6,984	9,968
Total Liabilities & Equity	12,913	13,220	13,798	14,280	15,169	16,054

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	152.27	184.36	139.13	255.01	263.87	205.29
Net Cash (Debt)	1,211	1,056	838.8	801.68	1,244	2,214
Net Cash Growth	14.01%	25.87%	4.63%	-35.54%	-43.82%	-
Net Cash Per Share	0.08	0.07	0.06	0.08	0.09	0.16
Filing Date Shares Outstanding	16,009	13,829	13,864	13,864	13,864	13,864
Total Common Shares Outstanding	16,009	13,829	13,864	13,864	13,864	13,864
Working Capital	1,729	1,386	1,007	709.67	1,942	3,338
Book Value Per Share	0.46	0.53	0.52	0.51	0.50	0.72
Tangible Book Value	6,945	6,839	6,658	6,450	6,312	9,240
Tangible Book Value Per Share	0.43	0.49	0.48	0.47	0.46	0.67
Buildings	-	5,286	5,119	5,229	5,401	5,665
Machinery	-	1,142	1,162	1,162	826.65	1,206
Construction In Progress	-	164.8	175.32	210.56	215.5	263.65